Android app on Google Play

Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment

February 20, 2013 2:06 PM EST Send to a Friend
Get Alerts PSTI Hot Sheet
Trade PSTI Now!
Join SI Premium – FREE
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.




You May Also Be Interested In


Related Categories

FDA, Insiders' Blog

Add Your Comment